Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment.

ABSTRACT:

Background and objectives

Esmethadone (dextromethadone; d-methadone; S-methadone (+)-methadone; REL-1017) is a low potency N-methyl-_D-aspartate (NMDA) receptor channel blocker that showed a rapid and sustained adjunctive antidepressant effects in patients with major depressive disorder with inadequate response to ongoing serotonergic antidepressant treatment. Previous studies indicated that esmethadone is partially excreted by the kidney (53.9% of the dose) and by the liver (39.1% of the dose).

Methods

Here we studied the pharmacokinetics and safety of esmethadone after a single oral dose of 25 mg in subjects with different stages of kidney and liver impairment.

Results

In subjects with a mild and moderate decrease in glomerular fraction rate (GFR), esmetha

SUBMITTER: Ferri N 

PROVIDER: S-EPMC11315824 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature